^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    eIF4A1 inhibitor

    Related drugs:
    Apply
    RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (NCT03675893)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    12/24/2018
    Primary completion :
    08/01/2026
    Completion :
    08/01/2029
    ER
    |
    ER positive
    |
    Verzenio (abemaciclib) • letrozole • zotatifin (eFT226) • metformin • samotolisib (LY3023414)
    Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (NCT04092673)
    Phase 1/2
    Effector Therapeutics
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    10/25/2019
    Primary completion :
    12/31/2024
    Completion :
    03/31/2025
    KRAS • FGFR • CCND1
    |
    KRAS mutation • KRAS G12C • HER-2 negative • KRAS G12 • FGFR amplification
    |
    Herceptin (trastuzumab) • Verzenio (abemaciclib) • Lumakras (sotorasib) • fulvestrant • zotatifin (eFT226)
    Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer (NCT05101564)
    Phase 2
    Stanford University
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    03/20/2023
    Primary completion :
    09/01/2025
    Completion :
    12/01/2026
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative
    |
    Piqray (alpelisib) • fulvestrant • Truseltiq (infigratinib) • letrozole • zotatifin (eFT226) • amcenestrant (SAR439859) • Soltamox (tamoxifen citrate)